Guide To The Turbulent Times At The Top of Teva
Executive Summary
While the rumor mill continues to turn over Pascal Soriot jumping ship from AstraZeneca to Teva, the experience of previous CEOs shows that the chair at the head of the Israeli drug maker’s table is a very hot seat indeed.
You may also be interested in...
Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.
Hansa Raises $121m To Fund Idefirix Launch
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.
Kiadis And Sanofi Sign Natural Killer Cell Therapy Pact
Sanofi is paying €17.5m upfront to combine a preclinical NK cell product with its anti-CD38 antibody Sarclisa and develop a multiple myeloma drug that potentially may prove more effective than J&J's Darzalex, Kiadis's CEO tells Scrip.
Need a specific report? 1000+ reports available
Buy Reports